Mylan Announces Final Approval for Bisoprolol Fumarate Tablets, USP

PITTSBURGH, Dec 19, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bisoprolol Fumarate Tablets USP, 5mg and 10mg. Bisoprolol Fumarate Tablets, which are the AB-rated generic version of Duramed Pharmaceuticals' Zebeta® Tablets, 5mg & 10 mg, had U.S. sales of approximately $27 million, for the 12-month period ended June 30, 2005, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.

Patrick Fitzgerald, or Kris King of Mylan Laboratories Inc., +1-724-514-1800